NSE: LAURUSLABS · 30 October 2026
- Laurus Labs has risen 10.25% over 2 trading sessions; today's move is +7.20%.
- Laurus Labs submitted its financial results for the quarter and half-year ended September 30, 2026, posting a 33% year-on-year rise in quarterly revenue to ₹2,206 crore and a 126% surge in net profit to ₹441 crore. EBITDA for the quarter jumped 78% to ₹762 crore with margins expanding to 34.5%, supported by solid execution across both the CDMO and Affordable Medicines divisions.
- Trading volume was 4.65 times the 20-day average daily volume.
Laurus Labs share price: 10.25% rise over 2 trading sessions
Laurus Labs Limited shares surged 7.20% today, trading near the upper end of the day's range between ₹2,208.30 and ₹2,405.50.
The broader market and sectoral backdrop provided solid support for the move. The benchmark Nifty rose 0.51%, while the Nifty Pharma sector index advanced 1.55%, reflecting strong positive momentum across pharmaceutical equities that helped underpin buying interest in sector leaders.
The strong price action follows the company's recent robust financial results and strategic expansion announcements for the quarter and half-year ended September 30, 2026. Laurus Labs reported a 33% year-on-year increase in revenue to ₹2,206 crore and a 126% jump in net profit to ₹441 crore, alongside definitive agreements to acquire a majority stake in Canada-based Galenvs Sciences and peptide-resin specialist SI&C Resins to bolster its CDMO and TIDES offerings. These announcements coincide with strong recent momentum, including a 22.11% return over the past 5 trading days.
76.53 lakh shares traded by 30 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 16.46 lakh shares (4.65 times). The five-day average daily volume was 23.94 lakh shares. Separately, the NSE report for 29 October 2026 showed 9.89 lakh shares delivered, representing 34.10% of that day’s traded volume. The same report recorded 109,993 trades.
The stock's sharp 7.20% gain and heavy trading volumes are directly backed by stellar Q2 FY27 financial results showing 126% profit growth and major strategic acquisitions in oligonucleotides and peptide resins announced on October 29, 2026.
Latest Company Developments
Laurus Labs submitted its financial results for the quarter and half-year ended September 30, 2026, posting a 33% year-on-year rise in quarterly revenue to ₹2,206 crore and a 126% surge in net profit to ₹441 crore. EBITDA for the quarter jumped 78% to ₹762 crore with margins expanding to 34.5%, supported by solid execution across both the CDMO and Affordable Medicines divisions.
Demonstrates robust operating leverage and earnings growth, directly strengthening fundamental investor sentiment.
The company announced definitive agreements to acquire a 60% stake in Canada-based Galenvs Sciences to scale up its oligonucleotide and precision magnetic nanoparticle capabilities, alongside a 52% stake acquisition in SI&C Resins for ₹32.50 crores to secure in-house peptide solid support resins and chromatography stationary phases.
Enhances Laurus Labs' integrated CDMO capabilities and supply chain security in high-growth peptide and oligonucleotide modalities.
The Board of Directors approved the payment of an interim dividend of Re. 1.00 per equity share of ₹2 each for the financial year 2026-27. The company fixed November 6, 2026, as the record date for determining shareholder eligibility, with payouts scheduled on or after November 19, 2026.
Reflects steady capital return to shareholders alongside ongoing aggressive growth capital expenditures.
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
a press release dated October 29, 2026, titled "Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 8.26% on 30 September 2026. This compares with 10.15% on 30 June 2026, a change of -1.89 percentage points.
The filing reported 38 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and integration timelines for newly acquired Galenvs Sciences and SI&C Resins
- Ramp-up and commercial utilization of the newly inaugurated peptide manufacturing facility in Vizag
- Sustained delivery volumes and cash market participation above the 20-day average volume benchmark
- Upcoming record date for interim dividend set for November 6, 2026
Other Dated Coverage
- Laurus Labs Share Price Today: Why LAURUSLABS Is Rising 2.85% | 29 October 2026 — 29 October 2026
- Laurus Labs Share Price Today: Rises 10.76% in 3 Trading Sessions | 28 October 2026 — 28 October 2026
- Laurus Labs Share Price Today: Why LAURUSLABS Is Rising 4.04% | 27 October 2026 — 27 October 2026
More Laurus Labs news and dated analysis →
Frequently Asked Questions
What is the latest Laurus Labs company news?
Laurus Labs submitted its financial results for the quarter and half-year ended September 30, 2026, posting a 33% year-on-year rise in quarterly revenue to ₹2,206 crore and a 126% surge in net profit to ₹441 crore. EBITDA for the quarter jumped 78% to ₹762 crore with margins expanding to 34.5%, supported by solid execution across both the CDMO and Affordable Medicines divisions.
How strong was Laurus Labs’s trading volume?
76.53 lakh shares traded, 4.65 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.